Treatment of HIV infection in pregnant women: Antiretroviral management options

Drugs

Volumn 64, Issue 5, 2004, Pages 471-488

  Loutfy, Mona R ^a   Walmsley, Sharon L ^b,c  

^a MONTREAL GENERAL HOSPITAL   (Canada)

^b UNIVERSITY HEALTH NETWORK   (Canada)

^c TORONTO GENERAL HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; AMPRENAVIR; ANTIRETROVIRUS AGENT; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; ENFUVIRTIDE; INDINAVIR; LAMIVUDINE; LOPINAVIR; NELFINAVIR; NEVIRAPINE; RITONAVIR; SAQUINAVIR; STAVUDINE; TENOFOVIR; ZALCITABINE; ZIDOVUDINE;

BREAST FEEDING; CESAREAN SECTION; CLINICAL TRIAL; DISEASE TRANSMISSION; DRUG EFFICACY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE STATUS; MITOCHONDRIAL DNA DISORDER; NONHUMAN; OSTEOMALACIA; PREGNANT WOMAN; PREVALENCE; REVIEW; RISK ASSESSMENT; RISK FACTOR; SIDE EFFECT; SINGLE DRUG DOSE; TERATOGENESIS; VIRUS LOAD;

ANTI-HIV AGENTS; FEMALE; HIV INFECTIONS; HUMANS; PREGNANCY; PREGNANT WOMEN; RANDOMIZED CONTROLLED TRIALS;

HUMAN IMMUNODEFICIENCY VIRUS;

EID: 1542721871     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-200464050-00002     Document Type: Review

References (73)

1. UNAIDS/WHO. AIDS epidemic: December 2002. Geneva: UNAIDS, 2002
2. De Cock KM, Mbori-Ngacha D, Marum E. Shadow on the continent: public health and HIV/AIDS in Africa in the 21st century. Lancet 2002; 360 (9326): 67-72
3. Dabis F, Ekpini ER. HIV-1/AIDS and maternal and child health in Africa. Lancet 2002; 359 (9323): 2097-104
4. Connor EM, Sperling RS, Gelber R, et al. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment: Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. N Engl J Med 1994; 331 (18): 1173-80
5. Fiscus SA, Adimora AA, Funk ML, et al. Trends in interventions to reduce perinatal human immunodeficiency virus type 1 transmission in North Carolina. Pediatr Infect Dis J 2002; 21: 664-8
6. European Collaborative Study. HIV-infected pregnant women and vertical transmission in Europe since 1986. AIDS 2001; 15 (6): 761-70
7. Yeni PG, Hammer SM, Carpenter CC, et al. Antiretroviral treatment for adult HIV infection in 2002: updated recommendations of the International AIDS Society-USA Panel. JAMA 2002; 288 (2): 222-35
8. CDC. US Public Health Service Task Force recommendations for the use of antiretroviral drugs in pregnant HIV-1-infected women for maternal health and interventions to reduce perinatal HIV-1 transmission in the United States [online]. Available from URL: http://www.aidsinfo.nih.gov/guidelines/ [Accessed 2003 Jun 16]
9. Ioannidis JPA, Abrams EJ, Ammann A, et al. Perinatal transmission of human immunodeficiency virus type 1 by pregnant women with RNA virus loads <1000 copies/ml. J Infect Dis 2001; 183 (4): 539-45
10. Coll O, Fiore S, Floridia M, et al. Pregnancy and HIV infection: a European consensus on management. AIDS 2002 Jun 2; 16 Suppl. 2: S1-S18
11. Burdge DR, Money DM, Forbes JC, et al. Canadian consensus guidelines for the management of pregnancy, labour and delivery and for postpartum care in HIV-positive pregnant women and their offspring (summary of 2002 guidelines). CMAJ 2003; 168 (13): 1671-4
12. Mofenson LM. Interaction between timing of perinatal human immunodeficiency virus infection and the design of preventive and therapeutic interventions. Acta Paediatr Suppl 1997 Jun; 421: 1-9
13. Tscherning-Casper C, Papadogiannakis N, Anvret M, et al. The trophoblastic epithelial barrier is not infected in full-term placentae of human immunodeficiency virus-seropositive mothers undergoing antiretroviral therapy. J Virol 1999; 73 (11): 9673-8
14. Rogers AB, Hoover EA. Maternal-foetal feline immunodeficiency virus transmission: timing and tissue tropisms. J Infect Dis 1998; 178 (4): 960-7
15. CDC. US Public Health Service Task Force: safety and toxicity of individual antiretroviral agents in pregnancy [online]. Available from URL: http://www.aidsinfo.nih.gov/guidelines/ [Accessed 2003 May 23]
16. Tuomala RE, Shapiro D, Mofenson LM, et al. Antiretroviral therapy during pregnancy and the risk of adverse outcome. N Engl J Med 2002; 346: 1863-70
17. European Collaborative Study. Exposure to antiretroviral therapy in utero or early life: the health of uninfected children born to HIV-infected women. J Acquir Immune Defic Syndr 2003; 32 (4): 380-7
18. European Collaborative Study. Swiss mother and child HIV cohort study: combination antiretroviral therapy and duration of pregnancy. AIDS 2000; 14 (18): 2913-20
19. Palumbo P, Holland B, Dobbs T, et al. Antiretroviral resistance mutations among pregnant human immunodeficiency virus type 1-infected women and their newborns in the United States: vertical transmission and clades. J Infect Dis 2001; 184 (9): 1120-6
20. Eshleman SH, Mracna M, Guay LA, et al. Selection and fading of resistance mutations in women and infants receiving nevirapine to prevent HIV-1 vertical transmission (HIV-1 NET 012). AIDS 2001; 15 (15): 1951-7
21. Mofenson LM, Munderi P. Safety of antiretroviral prophylaxis of perinatal transmission for HIV-infected pregnant women and their infants. J Acquir Immune Defic Syndr 2002; 30 (2): 200-15
22. Shaffer N, Chuachoowong R, Mock PA, et al. Short-course zidovudine for perinatal HIV-1 transmission in Bangkok, Thailand: a randomized controlled trial. Lancet 1999; 353 (9155): 773-80
23. Wiktor SZ, Ekpini E, Karon JM, et al. Short-course oral zidovudine for prevention of mother-to-child transmission of HIV-1 in Abidjan, Cote d'Ivoire: a randomised trial. Lancet 1999; 353 (9155): 781-5
24. Dabis F, Msellati P, Meda N, et al. 6-Month efficacy, tolerance, and acceptability of a short regimen of oral zidovudine to reduce vertical transmission of HIV in breastfed children in Cote d'Ivoire and Burkina Faso: a double-blind placebo-controlled multicentre trial. DITRAME Study Group: Diminution de la Transmission Mere-Enfant. Lancet 1999; 353 (9155): 786-92
25. Lallemant M, Jourdain G, Kim S, et al. A trial of shortened zidovudine regimens to prevent mother-to-child transmission of human immunodeficiency virus type 1. N Engl J Med 2000; 343 (14): 982-91
26. Guay LA, Musoke P, Fleming T, et al. Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomised trial. Lancet 1999; 354 (9181): 795-802
27. The Petra Study Team. Efficacy of three short-course regimens of zidovudine and lamivudine in preventing early and late transmission of HIV-1 from mother to child in Tanzania, South Africa, and Uganda (Petra Study): a randomised, double-blind, placebo-controlled trial. Lancet 2002; 359 (9313): 1178-86
28. Moodley D, Moodley J, Coovadia H, et al. A multicenter randomized controlled trial of nevirapine versus a combination of zidovudine and lamivudine to reduce intrapartum and early postpartum mother-to-child transmission of human immunodeficiency virus type 1: South African Intrapartum Nevirapine Trial (SAINT) Investigators. J Infect Dis 2003; 187 (5): 725-35
29. Mulder JW, Cooper DA, Mathiesen L, et al. Zidovudine twice daily in asymptomatic subjects with HIV infection and a high risk of progression to AIDS: a randomized, double-blind placebo-controlled study. AIDS 1994; 8 (3): 313-21
30. Sperling RS, Shapiro DE, Coombs RW, et al. Maternal viral load, zidovudine treatment, and the risk of transmission of human immunodeficiency virus type 1 from mother to infant: Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. N Engl J Med 1996; 335 (22): 1621-9
31. Leroy V, Karon JM, Alioum A, et al. Twenty-four month efficacy of a maternal short-course zidovudine regimen to prevent mother-to-child transmission of HIV-1 in West Africa. AIDS 2002; 16 (4): 631-41
32. Dorenbaum A, Cunningham CK, Gelber RD, et al. Two-dose intrapartum/newborn nevirapine and standard antiretroviral therapy to reduce perinatal HIV-1 transmission: a randomized trial. JAMA 2002; 288 (2): 189-98
33. Lorenzi P, Spicher VM, Laubereau B, et al. Antiretroviral therapies in pregnancy: maternal, foetal and neonatal effects. Swiss HIV Cohort Study, the Swiss Collaborative HIV and Pregnancy Study, and the Swiss Neonatal HIV Study. AIDS 1998; 12 (18): F241-7
34. Cooper ER, Charurat M, Mofenson L, et al. Combination antiretroviral strategies for the treatment of pregnant HIV-1 infected women and prevention of perinatal HIV-1 transmission: Women and Infants' Transmission Study Group. J Acquir Immune Defic Syndr Hum Retrovirol 2002; 29 (5): 484-94
35. Duran A, Hackim A, Zlatkes R, et al. Impact of combined antiretroviral therapy on perinatal HIV transmission [abstract no. WePeB5941]. Proceedings of XIVth International AIDS Conference; 2002 Jul 7-12; Barcelona
36. Melzi S, Chiesa E, Angeli E, et al. Use of different antiretroviral regimens during pregnancy in a cohort of 65 women in Italy [abstract no. MoPeD3682]. Proceedings of XIVth International AIDS Conference; 2002 Jul 7-12; Barcelona
37. de Vincenzi I, Gaillard P, Farley T. Impact of highly active antiretroviral treatment (HAART) during pregnancy and breastfeeding on mother-to-child HIV transmission (MTCT) and mother's health in developing countries [abstract no. WePeB5953]. Proceedings of XIVth International AIDS Conference; 2002 Jul 7-12; Barcelona
38. Garcia PM, Kalish LA, Pitt J, et al. Maternal levels of plasma human immunodeficiency virus type 1 RNA and the risk of perinatal transmission. N Engl J Med 1999; 341 (6): 394-402
39. Cao Y, Krogstad P, Korber BT, et al. Maternal HIV-1 viral load and vertical transmission of infection: the Ariel Project for the prevention of HIV transmission from mother to infant. Nat Med 1997; 3 (5): 549-52
40. Kovacs A, Wasserman SS, Burns D. Determinants of HIV-1 shedding in the genital tract of women. Lancet 2001; 358 (9293): 1593-601
41. Rich KC, Fowler MG, Mofenson LM, et al. Maternal and infant factors predicting disease progression in human immunodeficiency virus type 1-infected infants: Women and Infants Transmission Study Group. Pediatrics 2000; 105 (1): e8
42. The European Collaborative Study. Maternal viral load and vertical transmission of HIV-1: an important factor but not the only one. AIDS 1999; 13 (11): 1377-85
43. Mayaux MJ, Dussaix E, Isopet J, et al. Maternal virus load during pregnancy and the mother-to- child transmission of human immunodeficiency virus type 1: the French Perinatal Cohort Studies. J Infect Dis 1997; 175 (1): 172-5
44. Contopoulos-Ioannidis DG, Ioannidis JP. Maternal cell-free viremia in the natural history of perinatal HIV-1 transmission: a meta-analysis. J Acquir Immune Defic Syndr Hum Retrovirol 1998; 18 (2): 126-35
45. CDC. US Public Health Service Task Force recommendations for the use of antiretroviral drugs in pregnant HIV-1-infected women for maternal health and interventions to reduce perinatal HIV-1 transmission in the United States [online]. Available from URL: http://www.aidsinfo.nih.gov/ [Accessed 1998 Jan 30]
46. CDC. US Public Health Service Task Force recommendations for the use of antiretroviral drugs in pregnant HIV-1-infected women for maternal health and interventions to reduce perinatal HIV-1 transmission in the United States [online]. Available from URL: http://www.aidsinfo.nih.gov/ [Accessed 2000 Feb 25]
47. CDC. US Public Health Service Task Force recommendations for the use of antiretroviral drugs in pregnant HIV-1-infected women for maternal health and interventions to reduce perinatal HIV-1 transmission in the United States [online]. Available from URL: http://www.aidsinfo.nih.gov/ [Accessed 2000 Nov 3]
48. CDC. US Public Health Service Task Force Recommendations for the use of antiretroviral drugs in pregnant HIV-1-infected women for maternal health and interventions to reduce perinatal HIV-1 transmission in the United States [online]. Available from URL: http://www.aidsinfo.nih.gov/ [Accessed 2001 Jan 24]
49. CDC. US Public Health Service Task Force recommendations for the use of antiretroviral drugs in pregnant HIV-1-infected women for maternal health and interventions to reduce perinatal HIV-1 transmission in the United States [online]. Available from URL: http://www.aidsinfo.nih.gov/ [Accessed 2002 Feb 4]
50. CDC. US Public Health Service Task Force recommendations for the use of antiretroviral drugs in pregnant HIV-1-infected women for maternal health and interventions to reduce perinatal HIV-1 transmission in the United States [online]. Available from URL: http://www.aidsinfo.nih.gov/ [Accessed 2002 Aug 30]
51. Balani SK, Kauffman LR, deLuna FA, et al. Nonlinear pharmacokinetics of efavirenz (DMP-266), a potent HIV-1 reverse transcriptase inhibitor, in rats and monkeys. Drug Metab Dispos 1999; 27 (1): 41-5
52. Fundaro C, Genovese O, Rendeli C, et al. Myelomeningocele in a child with intrauterine exposure to efavirenz. AIDS 2002; 16 (2): 299-300
53. Blanche S, Tardieu M, Rustin P, et al. Persistent mitochondrial dysfunction and perinatal exposure to antiretroviral nucleoside analogues. Lancet 1999; 354 (9184): 1084-9
54. The Perinatal Safety Review Working Group. Nucleoside exposure in the children of HIV-infected women receiving antiretroviral drugs: absence of clear evidence for mitochondrial disease in children who died before 5 years of age in five United States cohorts. J Acquir Immune Defic Syndr Hum Retrovirol 2000; 25 (3): 261-8
55. Marcus K, Truffa M, Boxwell D, et al. Recently identified adverse events secondary to NRTI therapy in HIV-infected individuals: cases from the FDA's Adverse Event Reporting System (AERS) [abstract no. LB14]. In: Proceedings of 9th Conference of Retroviruses and Opportunistic Infections; 2002 Feb 24-28; Seattle (WA). Alexandria (VA): Foundation for Retrovirolog and Human Health, 2002
56. Hirsch MS, Brun-Vezinet F, D'Aquila RT, et al., for the International AIDS Society-USA Panel. Antiretroviral drug resistance testing in adult HIV-1 infection: recommendations of an International AIDS Society-USA Panel. JAMA 2000; 283 (18): 2417-26
57. Welles SL, Pitt J, Colgrove R, et al. HIV-1 genotypic zidovudine drug resistance and the risk of maternal-infant transmission in the Women and Infants Transmission Study Group. AIDS 2000; 14 (3): 263-71
58. Kully C, Yerly S, Erb P, et al. Codon 215 mutations in human immunodeficiency virus-infected pregnant women. J Infect Dis 1999 179 (3): 705-8
59. Eastman PS, Shapiro DE, Coombs RW, et al. Maternal viral genotypic zidovudine resistance and infrequent failure of zidovudine therapy to prevent perinatal transmission of human immunodeficiency virus type 1 in pediatric AIDS Clinical Trials Group Protocol 076. J Infect Dis 1998; 177 (3): 557-64
60. Giuliano M, Galluzzo T, Amici R, et al. Selection of resistance mutations in pregnant women receiving short-course antiretroviral regimens with ZDV and 3TC to prevent perinatal transmission (PETRA Study) [abstract no. 802-W]. In: Proceedings of 9th Conference of Retroviruses and Opportunistic Infections; 2002 Feb 24-28; Seattle (WA). Alexandria (VA): Foundation for Retrovirolog and Human Health, 2002
61. Mandelbrot L, Landreau-Mascaro A, Rekacewicz C, et al. Lamivudine-zidovudine combination for prevention of maternal-infant transmission of HIV-1. JAMA 2001; 285 (16): 2083-93
62. Nair P, Alger L, Hines S, et al. Maternal and neonatal characteristics associated with HIV infection in infants of seropositive women. J Acquir Immune Defic Syndr 1993; 6 (3): 298-302
63. The International Perinatal HIV Group. Duration of ruptured membranes and vertical transmission of HIV-1: a meta-analysis from 15 prospective cohort studies. AIDS 2001; 15 (3): 357-68
64. Mofenson LM, Lambert JS, Stiehm ER, et al. Risk factors for perinatal transmission of human immunodeficiency virus type 1 in women treated with zidovudine: Pediatric AIDS Clinical Trials Group Study 185 Team. N Engl J Med 1999; 341 (6): 385-93
65. Shey WI, Brocklehurst P, Sterne JA, et al. Vitamin A supplementation for reducing the risk of mother-to-child transmission of HIV infection. Cochrane Database Syst Rev 2002; (3): CD003648
66. Lambert JS, Watts DH, Mofenson L, et al. Risk factors for preterm birth, low birth weight, and intrauterine growth retardation in infants born to HIV-infected pregnant women receiving zidovudine: Pediatric AIDS Clinical Trials Group 185 Team. AIDS 2000; 14 (10): 1389-99
67. Shey WI, Brocklehurst P, Sterne JA, et al. Vaginal disinfection during labour for reducing the risk of mother-to-child transmission of HIV infection. Cochrane Database Syst Rev 2002; (3): CD003651
68. The European Mode of Delivery Collaboration. Elective cesarean-section versus vaginal delivery in prevention of vertical HIV-1 transmission: a randomised clinical trial. Lancet 1999; 353 (9158): 1035-9
69. The International Perinatal HIV Group. The mode of delivery and the risk of vertical transmission of human immunodeficiency virus type 1: a meta-analysis of 15 prospective cohort studies. N Engl J Med 1999; 340 (13): 977-87
70. Read JS, Tuomala R, Kpamegan E, et al. Mode of delivery and postpartum morbidity among HIV-infected women: the Women and Infants Transmission Study. J Acquir Immune Defic Syndr 2001; 26 (3): 236-45
71. Patel J, Melville S, Heath C, et al. Role of combination antiretroviral therapy and mode of delivery in perinatal HIV transmission (PHT), pediatric spectrum of disease project (PSD), United States, 1995-2000 [abstract no. 798-W]. In: Proceedings of 9th Conference of Retroviruses and Opportunistic Infections; 2002 Feb 24-28; Seattle (WA). Alexandria (VA): Foundation for Retrovirolog and Human Health, 2002
72. Ghosh MK, Kuhn L, West J, et al. Quantitation of human immunodeficiency virus type 1 in breast milk. J Clin Microbiol 2003; 41 (6): 2465-70
73. Nduati R, Richardson BA, John G, et al. Effect of breastfeeding on mortality among HIV-1 infected women: a randomised trial. Lancet 2001; 357 (9269): 1651-5